A Pilot Study of SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) as Maintenance Therapy
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Guadecitabine (Primary) ; Cyclophosphamide; Tumour cell vaccine-GVAX
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2020 Status changed from active, no longer recruiting to completed.
- 07 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 07 Dec 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.